The structure of JNK3 in complex with small molecule inhibitors: Structural basis for potency and selectivity

被引:115
|
作者
Scapin, G
Patel, SB
Lisnock, J
Becker, JW
LoGrasso, PV
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Metab Dis, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Mol Neurosci, San Diego, CA 92121 USA
来源
CHEMISTRY & BIOLOGY | 2003年 / 10卷 / 08期
关键词
D O I
10.1016/S1074-5521(03)00159-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The c-Jun terminal kinases (JNKs) are members of the mitogen-activated protein (MAP) kinase family and regulate signal transduction in response to environmental stress. Activation of JNK3, a neuronal-specific isoform, has been associated with neurological damage, and as such, JNK3 may represent an attractive target for the treatment of neurological disorders. The MAP kinases share between 50% and 80% sequence identity. In order to obtain efficacious and safe compounds, it is necessary to address the issues of potency and selectivity. We report here four crystal structures of JNK3 in complex with three different classes of inhibitors. These structures provide a clear picture of the interactions that each class of compound made with the kinase. Knowledge of the atomic interactions involved in these diverse binding modes provides a platform for structure-guided modification of these compounds, or the de novo design of novel inhibitors that could satisfy the need for potency and selectivity.
引用
收藏
页码:705 / 712
页数:8
相关论文
共 50 条
  • [41] Structure-Based Drug Design of Novel Aurora Kinase A Inhibitors: Structural Basis for Potency and Specificity
    Coumar, Mohane Selvaraj
    Leou, Jiun-Shyang
    Shukla, Paritosh
    Wu, Jian-Sung
    Dixit, Ajay Kumar
    Lin, Wen-Hsing
    Chang, Chun-Yu
    Lien, Tzu-Wen
    Tan, Uan-Kang
    Chen, Chun-Hwa
    Hsu, John T-A.
    Chao, Yu-Sheng
    Wu, Su-Ying
    Hsieh, Hsing-Pang
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) : 1050 - 1062
  • [42] Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors
    Cao, Jingrong
    Gao, Huai
    Bemis, Guy
    Salituro, Francesco
    Ledeboer, Mark
    Harrington, Edmund
    Wilke, Susanne
    Taslimi, Paul
    Pazhanisamy, S.
    Xie, Xiaoling
    Jacobs, Marc
    Green, Jeremy
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (10) : 2891 - 2895
  • [43] Enhanced potency of bivalent small molecule gp41 inhibitors
    Sofiyev, Vladimir
    Kaur, Hardeep
    Snyder, Beth A.
    Hogan, Priscilla A.
    Ptak, Roger G.
    Hwang, Peter
    Gochin, Miriam
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (01) : 408 - 420
  • [44] Potency variation of small-molecule chymase inhibitors across species
    Kervinen, Jukka
    Crysler, Carl
    Bayoumy, Shariff
    Abad, Marta C.
    Spurlino, John
    Deckman, Ingrid
    Greco, Michael N.
    Maryanoff, Bruce E.
    de Garavilla, Lawrence
    BIOCHEMICAL PHARMACOLOGY, 2010, 80 (07) : 1033 - 1041
  • [45] In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex
    Kim, Sang-Kyu
    Foitzik, Richard C.
    Li, Songhui
    Vinson, Andrew
    Shmaylov, Alex
    Jarvis, Karen
    James, Susan
    Walker, Scott R.
    York, Mark
    Cao, Benjamin
    Nilsson, Susan K.
    Johnstone, Ricky W.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [46] Discovery of brain penetrant JNK3 inhibitors as potential therapeutics for the treatment of Huntington\'s disease
    McGee, Kevin F.
    Duffy, Bryan C.
    Song, Ren Hua
    Conlon, Michael P.
    Kitchen, Douglas
    Lamers, Marieke
    Leonard, Philip
    Irigoyen, Macarena
    Luche, Michele
    Adolphson, Janet
    Bai, Mei
    Newell, Ryan
    Pastor, Eric
    Khademi, Shawn
    Hultman, Monica
    Ghandour, Haifa
    Michels, Peter
    Toledo-Sherman, Leticia
    Kiselyov, Alexander S.
    Beconi, Maria
    Munoz-Sanjuan, Ignacio
    Bard, Jonathan
    Dominguez, Celia
    Wityak, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [47] Assessing potency of c-Jun N-terminal kinase 3 (JNK3) inhibitors using 2D molecular descriptors and binary QSAR methodology
    Ijjaali, Ismail
    Petitet, Francois
    Dubus, Elodie
    Barberan, Olivier
    Michel, Andre
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (12) : 4256 - 4264
  • [48] NMR discovery and molecular-basis of small molecule inhibitors of STAT3
    Namanja, Andrew T.
    Buettner, Ralf
    Jove, Richard
    Chen, Yuan
    CANCER RESEARCH, 2014, 74 (19)
  • [49] Structural basis of AMPK regulation by small molecule activators
    Xiao, Bing
    Sanders, Matthew J.
    Carmena, David
    Bright, Nicola J.
    Haire, Lesley F.
    Underwood, Elizabeth
    Patel, Bhakti R.
    Heath, Richard B.
    Walker, Philip A.
    Hallen, Stefan
    Giordanetto, Fabrizio
    Martin, Stephen R.
    Carling, David
    Gamblin, Steven J.
    NATURE COMMUNICATIONS, 2013, 4
  • [50] Structural basis of AMPK regulation by small molecule activators
    Bing Xiao
    Matthew J. Sanders
    David Carmena
    Nicola J. Bright
    Lesley F. Haire
    Elizabeth Underwood
    Bhakti R. Patel
    Richard B. Heath
    Philip A. Walker
    Stefan Hallen
    Fabrizio Giordanetto
    Stephen R. Martin
    David Carling
    Steven J. Gamblin
    Nature Communications, 4